8-K: Veru Inc. Enters Forbearance Agreement with Onconetix Over $10 Million in Debt

Veru Inc. has agreed to a forbearance agreement with Onconetix, allowing the latter more time to repay $10 million in debt, while setting new payment terms.

Summary

• Veru Inc. has entered into a forbearance agreement with Onconetix, formerly known as Blue Water Vaccines Inc., regarding $10 million in outstanding promissory notes.
• The agreement addresses defaults by Onconetix on a $5 million note due April 19, 2024, and a $5 million note due September 30, 2024.
• Under the forbearance agreement, Onconetix will make an initial payment of $50,000 by April 29, 2024.
• Veru will forbear from exercising its rights and remedies related to the April 2024 note default and potential defaults related to Onconetix's acquisition of Proteomedix AG until the earlier of March 31, 2025, or an event of default.
• During the forbearance period, Onconetix will make monthly payments equal to 15% of certain cash receipts and 10% of net proceeds from specific financing or asset sale transactions.
• The remaining balance of the April 2024 note will be due at the end of the forbearance period, while the September 2024 note remains due on September 30, 2024.
• There is no guarantee that Veru will receive all payments under the agreement or that Onconetix will not default again.

Sentiment

Score: 4

Explanation: The document indicates a negative situation with a default on a promissory note, but the forbearance agreement provides a structured path for potential recovery. The sentiment is cautiously negative due to the existing default and the uncertainty of future payments.

Positives

• The forbearance agreement provides a structured repayment plan for Onconetix's debt.
• Veru will receive an initial payment of $50,000 by April 29, 2024.
• The agreement includes monthly payments based on Onconetix's cash receipts, potentially leading to consistent repayments.
• Veru retains its rights and remedies if Onconetix defaults again.

Negatives

• Onconetix has already defaulted on a $5 million promissory note.
• There is no guarantee that Veru will receive all payments under the forbearance agreement.
• The agreement extends the repayment timeline, potentially delaying full recovery of the debt.
• The agreement includes a risk of future default by Onconetix.

Risks

• There is a risk that Onconetix may default on its obligations under the forbearance agreement.
• Veru may not receive the full amount of the outstanding debt.
• The forbearance agreement could delay the recovery of the funds owed to Veru.
• The agreement relies on Onconetix's future cash receipts and transactions, which are uncertain.

Future Outlook

The document outlines a structured repayment plan for Onconetix's debt, but there is no guarantee of full repayment and a risk of future default. The agreement's success depends on Onconetix's future financial performance and transactions.

Management Comments

• Borrower and Holder acknowledge and agree that this Agreement has been negotiated in good faith.
• Borrower reaffirms that the Promissory Notes are valid, binding and enforceable against Borrower in accordance with their respective terms, as modified by provisions of this Agreement.
• The forbearance by Holder as provided herein shall result in a direct and substantial benefit to Borrower.

Industry Context

This agreement reflects a situation where a company, Veru, is managing debt recovery from another company, Onconetix, which has experienced financial difficulties. This is not uncommon in the biotech and pharmaceutical industries, where companies often rely on financing and strategic partnerships.

Comparison to Industry Standards

• Forbearance agreements are a common tool used in debt restructuring, especially when a borrower faces financial difficulties.
• The specific terms of this agreement, such as the percentage of cash receipts and transaction proceeds, are tailored to the specific circumstances of the companies involved.
• The 10% interest rate on the unpaid principal balance of the April 2024 Promissory Note is a typical rate for debt agreements of this nature.
• The agreement's reliance on future cash flows and transactions is a common approach in situations where a borrower has limited immediate cash resources.

Stakeholder Impact

• Shareholders of Veru Inc. face the risk of not fully recovering the $10 million debt.
• Employees of Veru Inc. may be affected by the financial implications of the debt recovery process.
• Creditors of Onconetix may be impacted by the terms of the forbearance agreement.
• The agreement may impact the future business operations of both Veru and Onconetix.

Next Steps

• Onconetix must make an initial payment of $50,000 by April 29, 2024.
• Onconetix must make monthly payments based on cash receipts starting May 20, 2024.
• Onconetix must make payments based on proceeds from certain transactions.
• Veru will monitor Onconetix's compliance with the forbearance agreement.
• The remaining balance of the April 2024 note is due at the end of the forbearance period, unless an earlier event of default occurs.

Key Dates

Keywords

Forbearance Agreement, Promissory Notes, Debt, Default, Onconetix, Veru Inc., Repayment, Asset Purchase Agreement, Proteomedix AG